Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07015892
PHASE3

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

Sponsor: Instituto de Investigación Biomédica de Salamanca

View on ClinicalTrials.gov

Summary

This is a phase III clinical trial that aims to evaluate whether increasing the dose of radiotherapy given twice a day can improve treatment outcomes in patients with localized small cell lung cancer (SCLC). All patients will receive standard chemotherapy with cisplatin and etoposide and will be randomly assigned to one of three radiotherapy regimens. The main objective is to determine whether this intensified radiotherapy improves progression-free survival and overall survival. The study will also compare two different dose escalation strategies and assess treatment side effects and patients' quality of life. This research may help identify a more effective treatment approach for patients with limited-stage SCLC and could contribute to improving long-term survival in this aggressive type of cancer

Official title: Phase III Randomized Clinical Trial to Evaluate the Efficacy and Safety of Twice-Daily Hyperfractionated Dose-Escalated Thoracic Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer (ESCALADOR Study)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2026-03-01

Completion Date

2028-12-31

Last Updated

2026-03-31

Healthy Volunteers

No

Interventions

RADIATION

Thoracic Radiotherapy 45 Gy BID

45 Gy delivered in 30 fractions of 1.5 Gy twice daily over three weeks, with 95% of the planning target volume (PTV) receiving at least 95% of the prescribed dose.

RADIATION

Thoracic Radiotherapy 60 Gy BID

60 Gy delivered in 40 fractions of 1.5 Gy BID. A minimum dose of 54 Gy will be accepted if organ-at-risk tolerance is exceeded.

RADIATION

Thoracic Radiotherapy SIB 45-54 Gy BID

45 Gy in 30 fractions (1.5 Gy BID) to PTV and 54 Gy in 30 fractions (1.8 Gy BID) to high-risk CTV. Both delivered simultaneously using 3D conformal planning.

Locations (13)

Complejo Asistencial Universitario de Salamanca

Salamanca, Salamanca, Spain

Hospital Universitario de Torrecardenas

Almería, Spain

Hospital Universitario de Cruces

Barakaldo, Spain

Instituto Catalán de Oncología

Girona, Spain

Hospital Dr. Negrin

Las Palmas de Gran Canaria, Spain

Hospital Gregorio Marañon

Madrid, Spain

Hospital Ramon y Cajal

Madrid, Spain

Hospital Universitario Virgen de Arrixaca

Murcia, Spain

Hospital Marques de Valdecilla

Santander, Spain

Complejo Hospitalario Universitario de Santiago

Santiago de Compostela, Spain

Genesis Care

Seville, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

Hospital La Fe

Valencia, Spain